Gerald Storch - Bristol Myers Independent Director

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 40px;;'>BMY</div>
BMY -- USA Stock  

0.45 Dividend

Mr. Gerald Leonard Storch is Independent Director of BristolMyers Squibb Company
Age: 62  Director Since 2012      
212 546-4020  www.bms.com
Storch has served as Chief Executive Officer of Storch Advisors since November 2017, a position he had also held from November 2013 until January 2015. He served as Chief Executive Officer of Hudson Bay Company from January 2015 until November 2017, a leading owner and operator of department stores, including Saks Fifth Avenue, Lord & Taylor, Hudson Bay Department Stores, Home Outfitters, Sakes OFF 5th, Kaufhof, Inno and the ecommerce business Gilt. He also served as Chairman of Toys "R" Us, Inc. from February 2006 until November 2013 and Chief Executive Officer of Toys "R" Us from February 2006 until May 2013. Prior to joining Toys "R" Us, Mr. Storch served as Vice Chairman of Target Corporationrationrationration. He joined Target in 1993 as Senior Vice President of Strategy and served in roles of increasing seniority over the next 12 years. Prior to joining Target, Mr. Storch was a partner at McKinsey & Company. He is a director of Fanatics, Inc. During the last five years, Mr

Gerald Storch Latest Insider Activity

Management Efficiency

The company has Return on Asset of 0.07 % which means that on every $100 spent on asset it made $0.07 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.17 % implying that it generated $0.17 on every 100 dollars invested.
The company has 25.8 B in debt with debt to equity (D/E) ratio of 159.7 . This implies that the company may be unable to create cash to meet all of its financial commitments. Bristol Myers Squibb has Current Ratio of 3.8 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Bruce BurlingtonAstrazeneca PLC
Robert KidderMerck Company
Ronald BlaylockPfizer
Eugene WashingtonJohnson Johnson
John MadiganGilead Sciences
Dimitri AzarNovartis AG
Jennifer DoudnaJohnson Johnson
Hubert JolyJohnson Johnson
Wendell WeeksMerck Company
Anne MulcahyJohnson Johnson
Daniel PodolskyGlaxoSmithKline PLC
Stacey CartwrightGlaxoSmithKline PLC
William KaelinEli Lilly And Company
Carla HillsGilead Sciences
Deborah DiSanzoAstrazeneca PLC
Dennis AusielloPfizer
Kevin LoftonGilead Sciences
Raul AlvarezEli Lilly And Company
Erik FyrwaldEli Lilly And Company
Nesli BasgozAllergan Plc
Kathi SeifertEli Lilly And Company

Company Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 30000 people.Bristol Myers Squibb Company (BMY) is traded on BATS Exchange in USA. It is located in 430 E. 29th Street 14th Floor, New York, NY 10016, United States and employs 30,000 people. Bristol Myers is listed under Pharmaceutical Products category by Fama And French industry classification.

Bristol Myers Squibb Leadership Team

Ann Powell, Chief Human Resource Officer, Senior Vice PresidentView
Togo West, Independent DirectorView
Karen Vousden, Independent DirectorView
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics OfficerView
Michael Bonney, Independent DirectorView
Alan Lacy, Independent DirectorView
Robert Bertolini, Independent DirectorView
Jose Baselga, Independent DirectorView
Charles Bancroft, Chief Financial Officer, Executive Vice President - Global Business OperationsView
Gerald Storch, Independent DirectorView
Louis Schmukler, Executive Vice President, President - Global Product Development and SupplyView
Michael Grobstein, Independent DirectorView
Christopher Boerner, Executive Vice President and Chief Commercial OfficerView
Phyllis Yale, Independent DirectorView
John Elicker, Senior Vice President - Corporate Affairs and Investor RelationsView
David Elkins, Executive Vice President and Chief Financial Officer Member of the Leadership TeamView
Anne Nielsen, Senior Vice President Chief Compliance and Ethics OfficerView
Karen Santiago, Senior Vice President, Corporate ControllerView
Rupert Vessey, Executive Vice President Research and Early Development Member of the Leadership TeamView
Giovanni Caforio, Chairman of the Board, Chief Executive OfficerView
Vicki Sato, Lead Independent DirectorView
Emmanuel Blin, Senior Vice President Chief Strategy OfficerView
Nadim Ahmed, Executive Vice President and President - HematologyView
Joseph Caldarella, Senior Vice President Corporate ControllerView
Julia Haller, Independent DirectorView
Laurie Glimcher, Independent DirectorView
Murdo Gordon, Executive Vice President Chief Commercial OfficerView
Lamberto Andreotti, Executive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. CommitteeView
Joseph Eid, Senior Vice President and Head of Global Medical Affairs Member of the Leadership TeamView
Thomas Lynch, Chief Scientific Officer, Executive Vice PresidentView
Lewis Campbell, Independent DirectorView
Dinesh Paliwal, Independent DirectorView
Theodore Samuels, Independent DirectorView
Samuel Moed, Senior Vice President - Strategic Planning and AnalysisView
Matthew Emmens, Independent DirectorView
Ann Judge, Chief Human Resource Officer, Senior Vice President Member of the Leadership TeamView
Sandra Leung, Executive Vice President, General CounselView
Paul Autenried, Chief Information Officer, Senior Vice PresidentView
Samit Hirawat, Executive Vice President Chief Medical Officer, Global Drug Development Member of the Leadership TeamView
Tim Power, Vice President of Investor RelationsView
Francis Cuss, Executive Vice President Chief Scientific OfficerView
Paul Biondi, Senior Vice President, Head of Strategy & Business DevelopmentView
Kathryn Metcalfe, Executive Vice President - Corporate Affairs Member of the Leadership TeamView
Peter Arduini, Independent DirectorView
Elizabeth Mily, Executive Vice President - Strategy & Business DevelopmentView

Stock Performance Indicators

Did you try this?

Run Price Ceiling Movement Now


Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
All  Next Launch Module

Bristol Myers Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol Myers and Novartis AG. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Please also try Fund Screener module to find activelly-traded funds from around the world traded on over 30 global exchanges.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page